Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy.
Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy.
复制标题
DOI：
10.1364/boe.4.000105
复制
发表时间：
2013-01-01
影响因子：
3.4
通讯作者：
Yodh AG
中科院分区：
文献类型：
--
作者：
Busch DR;Choe R;Rosen MA;Guo W;Durduran T;Feldman MD;Mies C;Czerniecki BJ;Tchou J;Demichele A;Schnall MD;Yodh AG
我们介绍并演示了一种新型的，基于弥漫性光学断层扫描（DOT）的乳腺癌特征用于监测新辅助化疗的进展。这种特征，称为恶性肿瘤的概率，是通过统计图像分析的总血红蛋白浓度，血氧饱和度，和散射系数分布在一个训练集人群的乳房断层扫描活检确诊乳腺癌。一项试点临床研究采用这种统计图像分析方法对三名患者进行化疗监测。虽然是初步的，但该研究展示了如何使用恶性参数来区分反应者和部分反应者，并与传统的DOT量化方案相比，展示了该方法的潜在效用。
We introduce and demonstrate use of a novel, diffuse optical tomography (DOT) based breast cancer signature for monitoring progression of neoadjuvant chemotherapy. This signature, called probability of malignancy, is obtained by statistical image analysis of total hemoglobin concentration, blood oxygen saturation, and scattering coefficient distributions in the breast tomograms of a training-set population with biopsy-confirmed breast cancers. A pilot clinical investigation adapts this statistical image analysis approach for chemotherapy monitoring of three patients. Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes.